Description
Regorafenib is an orally bioavailable multikinase inhibitor. This compound is clinically acceptable for treatment of metastatic colorectal cancer and non-responsive gastrointestinal stromal tumors. Regorafenib displays anticancer and anti-angiogenic properties, inhibiting primarily VEGF-R2 but also angiogenic kinases TIE2 and VEGF-R1/3, stromal kinases PDGF-R-Beta and FGF-R1, and oncogenic kinases KIT, RET, and B-Raf.
|
|||||||||||||||||||
Specifications | |||||||||||||||||||
|